AbbVie pays Gubra $350M to make late play for obesity space

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.87 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra.